• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在急性失代偿性心力衰竭患者的随访期间,贫血的改善和新发:特征和结局。

Improved and new-onset anemia during follow-up in patients with acute decompensated heart failure: Characteristics and outcomes.

机构信息

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.

出版信息

Medicine (Baltimore). 2021 Aug 13;100(32):e26892. doi: 10.1097/MD.0000000000026892.

DOI:10.1097/MD.0000000000026892
PMID:34397913
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8360432/
Abstract

There was no previous report on the prognostic impact of new-onset or improved anemia after discharge from acute decompensated heart failure (ADHF).We analyzed 771 patients with ADHF and who were followed in multicenters in Japan was divided into 4 groups based on the hemoglobin values at discharge and 6-month index visit: 373 patients (48.4%) with persistent anemia, 87 patients (11.3%) with new-onset anemia, 91 patients (11.8%) with improved anemia, and 220 patients (28.5%) without anemia.The primary outcome measure was a composite of all-cause death or HF hospitalization after index visit. The cumulative 6-month incidences of the primary outcome measure were 25.2% for persistent anemia, 18.5% for new onset anemia, 9.0% for improved anemia, and 9.2% for no anemia (log-rank P < .001). Compared with the no anemia group, the excess risk for the primary outcome measure remained significant in the persistent anemia group [hazard ratio (HR) 2.70, 95% confidence interval (95% CI), 1.45-5.44, P = .001] and in the new-onset anemia group (HR 2.73, 95% CI 1.19-6.25, P = .02), while it was not significant in the improved anemia group (HR 1.69, 95% CI 0.68-4.03, P = .25).Persistent and new-onset anemia at 6-month visit were associated with a subsequent higher risk for all-cause death or HF hospitalization in patients with ADHF, suggesting the importance of detecting anemia during follow-up.

摘要

尚无关于急性失代偿性心力衰竭(ADHF)出院后新发或改善的贫血对预后影响的报告。我们分析了在日本多中心接受随访的 771 例 ADHF 患者,根据出院时和 6 个月随访时的血红蛋白值将患者分为 4 组:持续性贫血患者 373 例(48.4%),新发贫血患者 87 例(11.3%),贫血改善患者 91 例(11.8%),无贫血患者 220 例(28.5%)。主要终点是随访时全因死亡或心力衰竭住院的复合终点。持续性贫血组、新发贫血组、贫血改善组和无贫血组的主要终点累积 6 个月发生率分别为 25.2%、18.5%、9.0%和 9.2%(对数秩检验 P<0.001)。与无贫血组相比,持续性贫血组(HR 2.70,95%CI 1.45-5.44,P=0.001)和新发贫血组(HR 2.73,95%CI 1.19-6.25,P=0.02)发生主要终点事件的风险仍然显著升高,而贫血改善组无显著差异(HR 1.69,95%CI 0.68-4.03,P=0.25)。ADHF 患者在 6 个月随访时持续性和新发贫血与全因死亡或心力衰竭住院的风险增加相关,提示在随访期间检测贫血的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c6/8360432/15afae945cea/medi-100-e26892-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c6/8360432/1d8dfadb9256/medi-100-e26892-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c6/8360432/d7ba5f47c551/medi-100-e26892-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c6/8360432/815416f73d2c/medi-100-e26892-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c6/8360432/15afae945cea/medi-100-e26892-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c6/8360432/1d8dfadb9256/medi-100-e26892-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c6/8360432/d7ba5f47c551/medi-100-e26892-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c6/8360432/815416f73d2c/medi-100-e26892-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c6/8360432/15afae945cea/medi-100-e26892-g004.jpg

相似文献

1
Improved and new-onset anemia during follow-up in patients with acute decompensated heart failure: Characteristics and outcomes.在急性失代偿性心力衰竭患者的随访期间,贫血的改善和新发:特征和结局。
Medicine (Baltimore). 2021 Aug 13;100(32):e26892. doi: 10.1097/MD.0000000000026892.
2
Gender Differences in Anemia and Survival in Patients Hospitalized for Acute Decompensated Heart Failure With Preserved or Reduced Ejection Fraction.射血分数保留或降低的急性失代偿性心力衰竭住院患者贫血与生存的性别差异
Am J Cardiol. 2017 Aug 1;120(3):435-442. doi: 10.1016/j.amjcard.2017.04.043. Epub 2017 May 11.
3
Association of admission and discharge anemia status with outcomes in patients hospitalized for acute decompensated heart failure: Differences between patients with preserved and reduced ejection fraction.急性失代偿性心力衰竭住院患者入院和出院时贫血状态与结局的关系:射血分数保留和降低患者之间的差异。
Eur Heart J Acute Cardiovasc Care. 2019 Oct;8(7):606-614. doi: 10.1177/2048872617730039. Epub 2017 Sep 7.
4
Outcomes of patients with anemia and acute decompensated heart failure with preserved versus reduced ejection fraction (from the ARIC study community surveillance).贫血合并急性失代偿性心力衰竭患者射血分数保留与降低时的结局(来自动脉粥样硬化风险社区研究的社区监测)
Am J Cardiol. 2014 Dec 15;114(12):1850-4. doi: 10.1016/j.amjcard.2014.09.024. Epub 2014 Sep 28.
5
Prognostic benefit of maintaining the hemoglobin level during the acute phase in patients with severely decompensated acute heart failure.严重失代偿性急性心力衰竭患者急性期维持血红蛋白水平的预后益处。
Heart Vessels. 2018 Mar;33(3):264-278. doi: 10.1007/s00380-017-1057-5. Epub 2017 Sep 27.
6
Association of Mineralocorticoid Receptor Antagonist Use With All-Cause Mortality and Hospital Readmission in Older Adults With Acute Decompensated Heart Failure.螺内酯类药物受体拮抗剂的使用与老年急性失代偿性心力衰竭患者全因死亡率和再入院率的关系。
JAMA Netw Open. 2019 Jun 5;2(6):e195892. doi: 10.1001/jamanetworkopen.2019.5892.
7
Pre-discharge anemia as a predictor of adverse clinical outcomes in patients with acute decompensated heart failure.急性失代偿性心力衰竭患者出院前贫血与不良临床结局的相关性。
Korean J Intern Med. 2019 May;34(3):549-558. doi: 10.3904/kjim.2017.337. Epub 2018 Mar 23.
8
The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge.托伐普坦剂量对急性失代偿性心力衰竭患者出院后心脏死亡率的影响。
Heart Vessels. 2018 Oct;33(10):1204-1213. doi: 10.1007/s00380-018-1177-6. Epub 2018 Apr 23.
9
Prognostic value of new-onset anemia as a marker of hemodilution in patients with acute decompensated heart failure and severe renal dysfunction.新发贫血作为急性失代偿性心力衰竭合并严重肾功能不全患者血液稀释标志物的预后价值。
J Cardiol. 2014 Jul;64(1):43-8. doi: 10.1016/j.jjcc.2013.11.007. Epub 2013 Dec 22.
10
Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction.心力衰竭伴射血分数降低患者的房颤类型与结局。
J Am Coll Cardiol. 2017 Nov 14;70(20):2490-2500. doi: 10.1016/j.jacc.2017.09.027.

引用本文的文献

1
Importance of non-cardiovascular comorbidities in atrial fibrillation and heart failure with preserved ejection fraction.非心血管合并症在心房颤动和射血分数保留的心力衰竭中的重要性。
ESC Heart Fail. 2025 Feb;12(1):389-400. doi: 10.1002/ehf2.15093. Epub 2024 Sep 21.
2
Verification of haemoglobin level to prevent worsening of prognosis in heart failure with preserved ejection fraction patients from the PURSUIT-HFpEF registry.验证血红蛋白水平以预防射血分数保留的心力衰竭患者预后恶化:来自 PURSUIT-HFpEF 注册研究。
ESC Heart Fail. 2024 Oct;11(5):3299-3311. doi: 10.1002/ehf2.14927. Epub 2024 Jul 1.
3
The effect of the four pharmacological pillars of heart failure on haemoglobin level.
心力衰竭的四大药物治疗支柱对血红蛋白水平的影响。
Ann Med Surg (Lond). 2024 Jan 29;86(3):1575-1583. doi: 10.1097/MS9.0000000000001773. eCollection 2024 Mar.
4
The Interplay of Comorbidities in Chronic Heart Failure: Challenges and Solutions.慢性心力衰竭合并症的相互作用:挑战与解决方案。
Curr Cardiol Rev. 2024;20(3):13-29. doi: 10.2174/011573403X289572240206112303.
5
Weight loss during follow-up in patients with acute heart failure: From the KCHF registry.随访期间急性心力衰竭患者的体重减轻:来自 KCHF 登记研究。
PLoS One. 2023 Jun 23;18(6):e0287637. doi: 10.1371/journal.pone.0287637. eCollection 2023.
6
Anaemia and Congestion in Heart Failure: Correlations and Prognostic Role.心力衰竭中的贫血与充血:相关性及预后作用
Biomedicines. 2023 Mar 21;11(3):972. doi: 10.3390/biomedicines11030972.